Yesterday, Oct. 5, 2015, 61 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $92.16 to $1,249,965.40.

Highlighted Stocks Traded by Insiders:

American Equity Investment Life (AEL) - FREE Research Report

Whitfield Harley A, who is Director at American Equity Investment Life, sold 1,000 shares at $23.79 on Oct. 5, 2015. Following this transaction, the Director owned 31,750 shares meaning that the stake was reduced by 3.05% with the 1,000-share transaction.

The shares most recently traded at $23.87, up $0.08, or 0.34% since the insider transaction. Historical insider transactions for American Equity Investment Life go as follows:

  • 4-Week # shares bought: 700
  • 4-Week # shares sold: 33,500
  • 12-Week # shares bought: 4,500
  • 12-Week # shares sold: 33,500
  • 24-Week # shares bought: 4,500
  • 24-Week # shares sold: 33,500

The average volume for American Equity Investment Life has been 775,800 shares per day over the past 30 days. American Equity Investment Life has a market cap of $1.8 billion and is part of the financial sector and insurance industry. Shares are down 18.67% year-to-date as of the close of trading on Monday.

American Equity Investment Life Holding Company, through its subsidiaries, develops and sells fixed index and fixed rate annuity products in 50 states and the District of Columbia. It issues fixed index annuities and fixed rate annuities, as well as single premium immediate annuities. The stock currently has a dividend yield of 0.86%. The company has a P/E ratio of 9.9. Currently, there are 3 analysts who rate American Equity Investment Life a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AEL - FREE

TheStreet Quant Ratings rates American Equity Investment Life as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, attractive valuation levels, good cash flow from operations, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full American Equity Investment Life Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Palatin Technologies (PTN) - FREE Research Report

Deveer Robert K Jr, who is Director at Palatin Technologies, bought 10,000 shares at $0.82 on Oct. 5, 2015. Following this transaction, the Director owned 222,393 shares meaning that the stake was boosted by 4.71% with the 10,000-share transaction.

The shares most recently traded at $0.79, down $0.03, or 3.42% since the insider transaction.

The average volume for Palatin Technologies has been 1.2 million shares per day over the past 30 days. Palatin Technologies has a market cap of $54.7 million and is part of the health care sector and drugs industry. Shares are up 7.53% year-to-date as of the close of trading on Monday.

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. Currently, there are 4 analysts who rate Palatin Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PTN - FREE

TheStreet Quant Ratings rates Palatin Technologies as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and poor profit margins. Get the full Palatin Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific (BSX) - FREE Research Report

Pratt Timothy A., who is EVP, GC & Chief Admin Officer at Boston Scientific, sold 3,500 shares at $17.34 on Oct. 5, 2015. Following this transaction, the EVP, GC & Chief Admin Officer owned 319,393 shares meaning that the stake was reduced by 1.08% with the 3,500-share transaction.

The shares most recently traded at $17.05, down $0.29, or 1.7% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares bought: 11,700
  • 4-Week # shares sold: 3,413
  • 12-Week # shares bought: 11,700
  • 12-Week # shares sold: 3,413
  • 24-Week # shares bought: 11,700
  • 24-Week # shares sold: 115,134

The average volume for Boston Scientific has been 8.2 million shares per day over the past 30 days. Boston Scientific has a market cap of $22.7 billion and is part of the health care sector and health services industry. Shares are up 28.83% year-to-date as of the close of trading on Monday.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Currently, there are 15 analysts who rate Boston Scientific a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.